Opendata, web and dolomites

iLCA SIGNED

Intelligent Live Cell Analysis [iLCA] to transform disease management through faster, and more regulatory robust, discovery, manufacture and monitoring of biologic drugs & cell therapies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 iLCA project word cloud

Explore the words cloud of the iLCA project. It provides you a very rough idea of what is the project "iLCA" about.

master    automation    banks    vivo    preparation    life    diagnostic    image    cells    transformative    workflow    behalf    entry    line    attributes    patients    cld    imaging    drug    cycle    validation    documentation    therapy    critical    therapies    provides    external    forefront    recording    fundraising    time    antibody    requirement    editing    markets    decades    penetration    disease    globally    marketed    attracting    engineering    market    ideally    intense    regulatory    dramatic    factories    manufactured    diverse    select    cell    speed    drugs    entire    last    themselves    faster    single    potentially    quality    ultimately    companies    live    suited    biologic    size    crude    sme    multiple    innovation    made    platform    consuming    workflows    commercial    competitor    aggressively    cheaper    continued    human    expensive    gene    ing    discovery    complete    manufacturing    diagnostics    shed    medicines    fti    competition    of    ex    global    relatively   

Project "iLCA" data sheet

The following table provides information about the project.

Coordinator
VALITACELL LTD 

Organization address
address: FOSTERS AVE. - MOUNT MERRION, BLACKROCK
city: DUBLIN 2
postcode: V94
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Project website https://www.valitacell.com/fti-ilca
 Total cost 3˙483˙633 €
 EC max contribution 2˙438˙543 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-EIC-FTI-2018-2020
 Funding Scheme IA
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2021-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VALITACELL LTD IE (DUBLIN 2) coordinator 1˙135˙667.00
2    SOLENTIM LTD UK (WIMBORNE) participant 708˙421.00
3    MICROCOAT BIOTECHNOLOGIE GMBH DE (BERNRIED) participant 594˙454.00

Map

 Project objective

The detailed analysis of live cells, as shed elements of a human disease process, cell therapies themselves or as factories for the production of biologic drugs, is attracting intense focus globally from diverse companies in automation, imaging, diagnostics and manufacturing. This proposal is made on behalf of a consortium of 3 European SME’s to support the validation and preparation for commercial take-up of the market entry application, Cell Line Development [CLD], of a new transformative technology at the forefront of these areas and is ideally suited for cell line development, antibody discovery, gene editing, cell therapy, antibody engineering and ex-vivo diagnostic workflows. Each workflow provides a dramatic increase in insight, control, speed and cost, ultimately resulting in faster, cheaper and more regulatory robust medicines for European patients. Biologic drugs are large in size and are manufactured from a single cell selected following an expensive, relatively crude and time consuming process - Cell Line Development. Our technology can select the 'Top' cell using a detailed analysis of the critical quality attributes along with providing complete image recording and documentation of the growth from a single cell [regulatory requirement]. This cell selection and control is essential as all resulting master and working cell banks are used over the entire life‐cycle of the marketed product that can last multiple decades. This FTI funding will enable market entry and validation & support external fundraising for the wider penetration of the global drug discovery, Cell therapy & ex-vivo diagnostic markets. This is a potentially transformative technology platform in a very large market with 1 current aggressively funded US competitor and our success will ensure competition, continued innovation and most importantly cheaper medicines for European patients.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ILCA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ILCA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.1.)

GoSafe (2019)

Restoring complete sensory ability for natural walking of amputees

Read More  

BIOSNAP (2019)

SMART, SUSTAINABLE & CONVENIENT UNIT DOSE PACKAGING

Read More  

Mag-ID (2019)

Magnetic identification

Read More